Cyheptamide

Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant.^[1]

Cyheptamide

Clinical data
Other names	Cyheptamine
Identifiers
IUPAC name tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide
CAS Number	7199-29-3
PubChem CID	23603
ChemSpider	22071
UNII	6R22P8K61P
KEGG	D03628
ChEMBL	ChEMBL1868301
CompTox Dashboard (EPA)	DTXSID6046551
ECHA InfoCard	100.027.792
Chemical and physical data
Formula	C16H15NO
Molar mass	237.302 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC2=CC=CC=C2C(C3=CC=CC=C31)C(=O)N
InChI InChI=1S/C16H15NO/c17-16(18)15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-8,15H,9-10H2,(H2,17,18) Key:APBVLLORZMAWKI-UHFFFAOYSA-N

Cyheptamide undergoes significant metabolic transformation in both animals and humans, primarily through hydroxylation pathways.^[2]

Cyheptamide exhibits moderate acute toxicity in animal models, with species-specific variations in lethal dose values.^[3]